Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.
image source: pexels
The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy
The team at the Infectious Diseases Institute, Kampala
DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.
RT @CatrionaWaitt: @UoLDolphin2 : it is great to end the year with protocol training for a new phase of the study. After lockdowns and challenges, such milestones feel even more special and worthy of celebration! https://t.co/Bhtr1Vbpn5
RT @CatrionaWaitt: Celebrating @UoLDolphin2 on #WorldAidsDay2021 It is essential that drugs are studied in the populations where they are to be used, and around 1.3 million women living with HIV become pregnant each year. Equity of access to research = better outcomes for communities. https://t.co/XPsnV5JSP9
RT @CatrionaWaitt: #EACS2021 Alexandra Calmy summarises landscape of increasing evidence for drug safety and efficacy in pregnancy and breastfeeding. Drawing from @pregnancyethics, highlights the need for a paradigm shift to increase equity of access to research. https://t.co/uL2td7SMw3